 Chemokine CXCL10
"Chemokine CXCL10" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR.
| Descriptor ID |
D054357
|
| MeSH Number(s) |
D12.644.276.374.200.120.500 D12.776.467.374.200.120.500 D23.125.300.120.500 D23.469.200.120.500 D23.529.374.200.120.500
|
| Concept/Terms |
Chemokine CXCL10- Chemokine CXCL10
- CXCL10, Chemokine
- CXCL10 Chemokine
- Chemokine, CXCL10
- Cytokine IP-10 Protein
- Cytokine IP 10 Protein
- IP-10 Protein, Cytokine
- gammaIP-10 Protein
- gammaIP 10 Protein
- Interferon-gamma-Inducible Protein of 10 kDa
- Interferon gamma Inducible Protein of 10 kDa
- Interferon-Inducible Protein 10
- Interferon Inducible Protein 10
- Small Inducible Cytokine B10
- CXC Chemokine IP-10
- CXC Chemokine IP 10
- Chemokine IP-10, CXC
- IFN-gamma-Inducible Protein, 10 kDa
- IFN gamma Inducible Protein, 10 kDa
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL10".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL10".
This graph shows the total number of publications written about "Chemokine CXCL10" by people in this website by year, and whether "Chemokine CXCL10" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 0 | 2 | 2 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemokine CXCL10" by people in Profiles.
-
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
-
Liu Y, Qu L, Liu Y, Roizman B, Zhou GG. PUM1 is a biphasic negative regulator of innate immunity genes by suppressing LGP2. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6902-E6911.
-
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
-
Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
-
Wei D, Li NL, Zeng Y, Liu B, Kumthip K, Wang TT, Huo D, Ingels JF, Lu L, Shang J, Li K. The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. J Biol Chem. 2016 Jun 03; 291(23):12294-309.
-
Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015 Jul 14; 113(2):327-35.
-
Tortelli F, Pisano M, Briquez PS, Martino MM, Hubbell JA. Fibronectin binding modulates CXCL11 activity and facilitates wound healing. PLoS One. 2013; 8(10):e79610.
-
Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, Knechtle SJ, Friedewald J, Becker YT, Sharma VK, Williams NM, Chang CS, Hoang C, Muthukumar T, August P, Keslar KS, Fairchild RL, Hricik DE, Heeger PS, Han L, Liu J, Riggs M, Ikle DN, Bridges ND, Shaked A. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013 Jul 04; 369(1):20-31.
-
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.
-
Harari OA, Alcaide P, Ahl D, Luscinskas FW, Liao JK. Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res. 2006 May 12; 98(9):1134-40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|